[CORT] Corcept Therapeutics Incorporated

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 8.12 Change: 0.21 (2.65%)
Ext. hours: Change: 0 (0%)

chart CORT

Refresh chart

Strongest Trends Summary For CORT

CORT is in the long-term down -41% below S&P in 2 years and up 745% in 9 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Corcept Therapeutics Incorporated, a pharmaceutical company, is engaged in the discovery, development, and commercialization of drugs for the treatment of metabolic, psychiatric, and oncologic disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing?s syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing mifepristone, an active ingredient in Korlym, which is in Phase III study for treatment of the psychotic features of psychotic depression; and in Phase I study for the treatment of triple-negative breast cancer. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta D

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 72.68% Sales Growth - Q/Q12.07% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-46.21% ROE-210.77% ROI
Current Ratio2.85 Quick Ratio2.76 Long Term Debt/Equity0.77 Debt Ratio1.47
Gross Margin96.87% Operating Margin-58.27% Net Profit Margin-69.1% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities15.52 M Cash From Investing Activities-30 K Cash From Operating Activities-1.78 M Gross Profit9.8 M
Net Profit-4.83 M Operating Profit-4.03 M Total Assets48.22 M Total Current Assets44.19 M
Total Current Liabilities15.53 M Total Debt32.78 M Total Liabilities37.65 M Total Revenue10.1 M
Technical Data
High 52 week19.69 Low 52 week10.03 Last close11.49 Last change0.79%
RSI64.97 Average true range0.69 Beta1 Volume325.31 K
Simple moving average 20 days1.55% Simple moving average 50 days-11.87% Simple moving average 200 days-18.97%
Performance Data
Performance Week-2.63% Performance Month-16.8% Performance Quart-6.2% Performance Half-16.8%
Performance Year-28.59% Performance Year-to-date-14% Volatility daily4.55% Volatility weekly10.17%
Volatility monthly20.83% Volatility yearly72.17% Relative Volume267.92% Average Volume1.91 M
New High New Low

News

2019-03-19 19:46:00 | Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Corcept Therapeutics Incorporated

2019-03-19 17:52:44 | INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corcept Therapeutics Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-03-19 11:55:00 | Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Corcept Therapeutics Incorporated

2019-03-19 10:35:00 | CLASS ACTION UPDATE for ATVI, CORT and USX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-03-19 10:11:00 | Bronstein, Gewirtz & Grossman, LLC Class Action Announcement: VALE, CORT & UMC

2019-03-19 09:30:00 | CORT Class Action Alert: Hagens Berman Alerts Corcept Therapeutics NASDAQ: CORT Investors to Securities Class Action and May 13, 2019 Lead Plaintiff Deadline

2019-03-19 08:00:00 | Corcept CORT Class Action Lawsuit: Bernstein Liebhard LLP Announces a Securities Class Action Lawsuit Against Corcept Therapeutics Incorporated – CORT

2019-03-18 18:14:00 | IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corcept Therapeutics Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-03-18 17:25:00 | FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CORT, VALE and BPI

2019-03-18 16:55:00 | Corcept CORT Class Action Lawsuit: Bernstein Liebhard LLP Announces A Securities Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

2019-03-18 16:45:00 | SHAREHOLDER ALERT: CORT INGN USX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

2019-03-18 15:59:00 | INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Corcept Therapeutics Incorporated Investors

2019-03-18 15:00:00 | Corcept Therapeutics Incorporated CORT Bronstein, Gewirtz & Grossman, LLC Announces Class Action and Lead Deadline: May 13, 2019

2019-03-18 11:57:31 | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CORT, TYME, TAP and UMC

2019-03-18 10:18:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

2019-03-18 10:10:00 | Bronstein, Gewirtz & Grossman, LLC Class Action Update: VALE, CORT & UMC

2019-03-18 08:30:00 | Corcept Therapeutics Appoints Former Amgen Development Executive, Andreas Grauer, M.D., as Chief Medical Officer

2019-03-17 11:00:00 | CLASS ACTION UPDATE for ZIV, CORT, SVXY and BRS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-03-15 23:48:00 | IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corcept Therapeutics Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-03-15 20:00:00 | Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated CORT

2019-03-15 19:41:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

2019-03-15 15:47:09 | SHAREHOLDER ALERT: ZIV CORT GE WTW: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

2019-03-15 15:06:57 | FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ZIV, CORT, UXIN and GE

2019-03-15 15:02:38 | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Corcept Therapeutics Incorporated To Contact The Firm

2019-03-15 13:43:00 | EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Corcept Therapeutics Incorporated – CORT

2019-03-15 12:05:00 | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MAXR, GSM and CORT

2019-03-15 11:10:00 | Corcept Therapeutics Incorporated CORT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation

2019-03-14 19:30:00 | Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated CORT and Encourages CORT Investors to Contact the Firm

2019-03-14 17:05:00 | Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of Corcept Therapeutics Incorporated Investors CORT

2019-03-11 14:54:00 | Here's Why Corcept Therapeutics Shares Rose 11.5% in February

2019-03-06 17:20:06 | Short Squeeze on Corcept Therapeutics

2019-03-01 08:52:17 | What Should We Expect From Corcept Therapeutics Incorporated’s NASDAQ:CORT Earnings In The Next Couple Of Years?

2019-02-26 14:40:07 | Corcept CORT Q4 Earnings Beat Estimates, Revenues In Line

2019-02-26 13:57:16 | Corcept Therapeutics Incorporated CORT Q4 2018 Earnings Conference Call Transcript

2019-02-26 02:14:38 | Edited Transcript of CORT earnings conference call or presentation 25-Feb-19 10:00pm GMT

2019-02-25 16:05:00 | Corcept Therapeutics Announces fourth quarter and full-year 2018 Audited Financial Results and provides corporate update

2019-02-19 16:05:00 | Corcept Therapeutics To Announce Audited Financial Results, Provide Corporate Update And Host Conference Call

2019-02-11 20:31:00 | Glancy Prongay & Murray LLP Announces Investigation on Behalf of Corcept Therapeutics Incorporated Investors

2019-02-11 07:20:00 | Recent Analysis Shows Corcept Therapeutics, CDK Global, Dynavax Technologies, ICU Medical, American Vanguard, and Cabot Market Influences — Renewed Outlook, Key Drivers of Growth

2019-02-08 08:50:01 | Options Traders Expect Huge Moves in Corcept CORT Stock

2019-02-07 16:13:00 | INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Corcept Therapeutics Incorporated Investors

2019-02-06 08:29:08 | Investors Are Undervaluing Corcept Therapeutics Incorporated NASDAQ:CORT By 49.63%

2019-02-05 16:34:00 | Investor Alert: Kaplan Fox Investigates Corcept Therapeutics Incorporated

2019-02-05 14:58:40 | Puts Pop Amid Drug Stock's Roller-Coaster Session

2019-02-01 12:17:00 | Here's Why Corcept Therapeutics Fell as Much as 13.7% Today

2019-01-31 16:05:00 | Corcept Therapeutics Announces Fourth Quarter and Full-Year 2018 Preliminary Selected Financial Results; Provides 2019 Revenue Guidance

2019-01-25 17:00:03 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Corcept Therapeutics Incorporated

2019-01-25 15:55:00 | Here's Why Corcept Therapeutics Stock Fell as Much as 18.5% Today

2019-01-25 14:17:12 | Corcept Puts Active After Negative Report

2019-01-11 13:15:38 | Can Corcept Therapeutics Incorporated NASDAQ:CORT Maintain Its Strong Returns?